🔗 Share this article

While America proceeds with sweeping adjustments to its vaccination recommendations, an unexpected name has emerged in a surprising turn: Høeg, a Danish American physician and epidemiologist who rose to prominence by questioning COVID-19 vaccines during the pandemic and has concentrated on possible deaths following COVID-19 vaccination in her recent tenure at the FDA.

Planned Shifts to Pediatric Vaccine Program

Public health authorities planned to unveil radical changes to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s vaccine program, sources say – a significant shift that would place the US out of step with much of the international standard with insufficient data for public health gain. The planned update has been postponed until the next year.

Rather than Vinay Prasad, Høeg is set to present at the gathering. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this year.

A New Direction at the Agency

This interim role could signify a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for halting some pediatric immunization guidelines in the US so as to align more like the Danish model, a country with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

To date public appearances, she has continued to focus on immunizations – typically the purview of Dr. Prasad, director of the FDA’s CBER – rather than drug regulation.

Doubts Over Background

Høeg has no obvious experience in medication creation, oversight or management, which has been customary for past leaders of the CBER. She has served at the FDA as a key advisor to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for running the drug-regulation department, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Former heads of the center would “understand legal statutes and the science of medication creation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that prior appointees who ran the center have had.”

The drug center has an enormous workload at the FDA, she pointed out.

“Many people just zeroes in on the new drug program, but the generic program approves numerous generic medications. There is also a biosimilars division, over-the-counter program and so forth, and each of these have to be looked after,” Dr. Woodcock said. “The thing you neglect, that is the part that I always told people is going to cause problems.”

There is also, a substantial administrative element to the job, which oversees more than 5,000 personnel. “It’s a enormous leadership role, if you perform it correctly,” the former official added.

Agency Reaction and Disputed Policies

When asked about concerns about Høeg’s fitness for the role and whether this assignment indicates greater collaboration among FDA leaders on vaccines, a spokesperson stated that the “inquiries are based on incorrect assumptions”.

“Her experience matches the duties of her role,” the official explained, citing the period Dr. Høeg spent counseling the agency head on “medication safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed expedited drug-approval program that apparently troubled her predecessors. “By what process are these therapies being chosen for this voucher program? Who makes the decisions?” Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he said, “the FDA looks to be trending towards less stringent regulations of most medications, with the exception of shots.”

Public History on Immunizations

Regarding vaccines, Høeg has a more documented, if problematic, track record, some experts have noted. She published a analysis using unverified public submissions to estimate the frequency of heart inflammation after Covid vaccination. She advised the Florida chief medical officer Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are more dangerous than they are.

Among her “policy goals” for the new government included altering regulations for new vaccines and discontinuing “non-essential” vaccines, she said post-election on a podcast. At the FDA, Dr. Høeg has allegedly proposed preventing adolescent males from receiving COVID-19 vaccinations.

“She’s an thorough true believer who begins with her conclusions and reverse-engineers to accommodate the science in a highly deceptive, dishonest way,” Dr. Howard argued.

Taking Control and a “Revenge Tour”

Høeg became part of other skeptics, {like|